ALIBABA-GROUP
17.9.2020 07:02:08 CEST | Business Wire | Press release
During Apsara Conference 2020, the digital technology and intelligence backbone of Alibaba Group, unveiled a series of artificial intelligence (AI) powered solutions which are set to transform and digitalize the way sports entertainment was traditionally organized, broadcast and consumed. The solutions are designed to bring spectators closer to the events’ center stage for more personalized and interactive engagement, while helping organizers and broadcasters operate more efficiently, effectively and securely.
Event organizers are set to benefit considerably from Alibaba Cloud’s Event Simulation Services (ESS) . Running on cloud and powered by elastic compute, ESS can help organizers plan the layout of indoor venues virtually, optimizing the position of equipment and facilities, without having to move or commission a single piece of physical kit. With the ability to create a digital twin, ESS negates the time, expense and risk of physical tests and run-throughs, providing a comprehensive digital examination of a venue for all key stakeholders. When it comes to event broadcasting planning, ESS enables broadcasters to simulate and test different camera positions before installing camera tracks, thereby offering audiences the best point of view. Furthermore, ESS provides organizers with a wealth of insights for post-event analysis for more effective future planning.
For large-scale events, crowd management and access control could be time-consuming and cumbersome to coordinate. The typical paper-based accreditation system is not effective enough, especially at a time when venue coordinators are working hard to maintain social distancing measures.
Alibaba Cloud has developed a Digital Badge System which embeds access control and essential event information with digital accreditation. Developed to be simple to use, the digital badge system negates the need to print a paper ticket, not only being more environmentally friendly, but also reducing the risk of access pass counterfeiting. When using the digital badge, cards that carry important information such as maps, event times and organizer contact details, can be issued within seconds and on demand, removing the inventory problems often associated with paper-based systems. Card holders can also receive card expiration notices and other important notifications in real-time. In addition, event organizers have the option to embed health advisory information in the event of COVID-19 outbreaks.
Broadcasters and journalists are imperative in bringing the joy and excitement of sports stories to fans around the world. To improve their experience when attending press conferences, Alibaba Cloud has launched Press Conference on Cloud to facilitate virtual media briefings using proven live and on-demand streaming technologies. The solution broadens the reach and increases efficiency for journalists, who do not need to be physically present in order to join press conferences, saving them valuable time in crafting news stories, as well as the hassles of travelling to different venues in gigantic sports parks. Furthermore, with Press Conference on Cloud, reporters may even choose to attend more than one briefing happening in different locations at the same time to maximise their efficiency and productivity.
To bring fans closer to sports events, Alibaba Cloud also launched Fan Video Hub to enable sports fans from all over the world to support their favourite teams and athletes more personally, regardless of their location. The AI-powered technology can act as an efficient aggregator, which is able to collect and filter real-time videos uploaded by fans from all over the world to a variety of social network platforms, before broadcasting them onto designated online platforms, or in venues where the event being enjoyed is going on. Organizers of sports events can initiate special projects, encouraging fans to create motivating and personalized videos that will eventually be displayed in sports stadiums.
“As a global leading cloud service provider, we are excited to see our mature technology innovations to be used to support the digital transformation of some of the largest international sports events,” said Selina Yuan, President of International Business, Alibaba Cloud Intelligence. “For example, with Alibaba Cloud’s trusted infrastructure and services, we are able to work with stadiums and event managers to create even more thrilling and immersive experiences for fans, wherever they’re based. More importantly, health and safety has to be front of mind at all venues and events, and our solutions help event organizers deliver on their post-pandemic responsibilities through reduced and unnecessary travel. We want to maximize the thrill of sporting achievements, while enabling event organizers to work safely and even more efficiently with fans and global broadcasters.”
Alibaba Cloud is committed to digitalizing sports events through helping broadcasters revolutionalize the experience. In September 2018, together with Olympic Broadcasting Services (OBS), Alibaba Cloud launched OBS cloud, which was developed to transform the process for bringing the Olympic Games to viewers. Alibaba Cloud is also the official cloud services partner of the International Olympic Committee.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com ), the digital intelligence and technology backbone of Alibaba Group, is among the world’s top three IaaS providers, according to Gartner, and the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and government organisations. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916006013/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom